NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $170.7 million in its first quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $2.03.

The results fell short of Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.72 per share.

The biotechnology company posted revenue of $108.8 million in the period, also falling short of Street forecasts. Nine analysts surveyed by Zacks expected $114.4 million.

Ultragenyx expects full-year revenue in the range of $500 million to $530 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

For copyright information, check with the distributor of this item, STATS Perform dba Automated Insights. , source Associated Press News